CN102627643A - Refining method for ganciclovir - Google Patents
Refining method for ganciclovir Download PDFInfo
- Publication number
- CN102627643A CN102627643A CN2012101041870A CN201210104187A CN102627643A CN 102627643 A CN102627643 A CN 102627643A CN 2012101041870 A CN2012101041870 A CN 2012101041870A CN 201210104187 A CN201210104187 A CN 201210104187A CN 102627643 A CN102627643 A CN 102627643A
- Authority
- CN
- China
- Prior art keywords
- ganciclovir
- guanine
- purification
- bullion
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of chemical refining, in particular to a refining method for ganciclovir. The refining method specifically comprises the following steps of: heating to dissolve the ganciclovir by using lower fatty acid aqueous solution; filtering off insoluble substances therein; cooling, crystallizing and suction-filtering filtrate; treating through inorganic alkali solution and then adjusting to be neutral, wherein the content of guanine impurity in the ganciclovir is reduced by a method of obtaining solid through crystallization. According to the method of reducing the content of the guanine impurity in the ganciclovir adopted in the refining method, the content of the guanine impurity can be reduced to be below 0.50 percent; and the method has the advantages of no need of repeating crystallization operation, short refining period, low energy consumption and high yield and is suitable for large-scale industrial production.
Description
Technical field
The present invention relates to the chemical refining technical field, especially the process for purification of ganciclovir.
Background technology
Ganciclovir chemistry 9-(1,3-dihydroxyl-2-third oxygen methyl) by name-guanine is the ucleosides antiviral drug, but competitive inhibition DNA polymerase, and mix among the DNA of virus and host cell, it is synthetic to suppress DNA.Ganciclovir is the verivate of acyclovir, and is more effective than acyclovir, and antiviral spectrum is wider; Cytomegalovirus there is the high degree of specificity effect; The effect that suppresses human cytomegalic inclusion disease virus is better than acyclovir, has certain effect, these article to be released by U.S. Syntex company to herpes simplex virus I-type and II type, varicella zoster virus, Epstein-Barr virus etc.; In approval listing in 1988, be the choice drug of treatment cytomegalovirus infection.
The compound method of ganciclovir mainly contains following two kinds: 1. diacetyl guanine (or single acetyl guanine; The perhaps mixture of single acetyl guanine and diacetyl guanine) with 1; 3-dihalo-2-(acetoxyl group methoxyl group) propane carries out condensation reaction; Carry out replacement(metathesis)reaction with acetate then and obtain the triacetyl ganciclovir, obtain ganciclovir through hydrolysis reaction again; 2. acetyl guanine (or single acetyl guanine; The perhaps mixture of single acetyl guanine and diacetyl guanine) with 1; 3-diacetoxy-2-(acetoxyl group methoxyl group) propane) carrying out condensation reaction prepares the triacetyl ganciclovir, obtains ganciclovir through hydrolysis reaction then, 1. and 2. prepares ganciclovir as stated above; Contain guanine impurity in the product, its structural formula is following.
The guanine foreign matter content is higher relatively in the ganciclovir that 1. method prepares; Generally reach more than 5%, the method for guanine foreign matter content is in the reduction ganciclovir of bibliographical information: under heating condition, with water dissolution bullion ganciclovir; Add big carbon content active then and carry out adsorption treatment; The crystallization of heat filtering postcooling is filtered, and repeats that described hot water is broad to be separated-charcoal absorption-crystallisation by cooling-filtration procedure again; Until obtaining qualified ganciclovir, need the repetition aforesaid operations more than 8 times approximately; The guanine foreign matter content can obtain qualified ganciclovir generally below 1% through 3~5 above-mentioned purification operations in the ganciclovir that 2. method prepares; There is the refining problem that the cycle is long, energy consumption is high and yield is low in process for purification of the prior art.
Summary of the invention
The technical problem that the present invention will solve is: the process for purification that guanine foreign matter content in the reduction ganciclovir that a kind of refining cycle is short, energy consumption is low and yield is high is provided.
The technical solution adopted for the present invention to solve the technical problems is: a kind of process for purification of ganciclovir specifically may further comprise the steps:
(1) in 1g: the ratio of 10~20ml adds the dissolving of lower fatty acid heated in water solution with the ganciclovir bullion, and the ratio that adds 0.05~0.10g in per 1 gram ganciclovir bullion adds gac, refluxes 30 minutes, filters insolubles, gets the filtrating crystallisation by cooling;
(2) suction filtration gained filtrating and crystalline mixture; Getting crystallized product, to use mass concentration be 2~10% inorganic alkali solution stir process 0.5~2.0 hour at room temperature; With hydrochloric acid system is transferred to neutrality then, stirred crystallization is after 2~6 hours, suction filtration; Get the crystallized product oven dry, get the qualified ganciclovir of guanine foreign matter content.
Lower fatty acid in the said step (1) is formic acid or acetate, and mass concentration is 5~30%, ganciclovir bullion and the preferred 1g of lower aliphatic aqueous acid ratio: 15ml; Mineral alkali in the step (2) is sodium hydroxide or Pottasium Hydroxide, mass concentration preferred 5%.
Lower fatty acid preferable formic acid in the said step (1); The preferred sodium hydroxide of mineral alkali in the step (2).
The guanine foreign matter content was greater than 4% o'clock in the ganciclovir bullion; If the guanine foreign matter content is smaller or equal to 0.5% in the ganciclovir that from the lower aliphatic aqueous acid, filters out; Then carry out subsequent operationss such as inorganic alkali solution processing; If guanine content is greater than 0.5%, then needs again once, and then carry out subsequent operations such as inorganic alkali solution processing with the processing of lower aliphatic aqueous acid.
The present invention utilizes inorganic alkali solution to handle the solid of in the lower aliphatic aqueous acid, separating out, and is to be hydrolyzed to ganciclovir again for a small amount of ganciclovir acylate that ganciclovir and lower fatty acid are generated.
The present invention utilizes guanine relatively big character of solubleness in aqueous solutions of organic acids; Adopt lower aliphatic aqueous acid heating for dissolving ganciclovir, filter out insolubles wherein, the filtrating crystallisation by cooling; Suction filtration; Handle through inorganic alkali solution, be transferred to neutrality then, obtain the content that the solid mode reduces guanine impurity in the ganciclovir with crystallization.
Beneficial effect: the method for guanine foreign matter content can be reduced to the guanine foreign matter content below 0.50% in the reduction ganciclovir of the present invention; This method need not repeatedly the recrystallization operation; Have the advantage that the refining cycle is short, energy consumption is low, yield is high, be suitable for large-scale industrial production.
Embodiment
Below in conjunction with specific embodiment the present invention is elaborated, but the present invention is not limited to following specific embodiment.
Embodiment 1
A kind of guanine content is the process for purification of 3.68% 20g ganciclovir bullion, may further comprise the steps:
(1) drop into reaction flask with 20% formic acid solution 300ml, be warmed up to backflow, keep refluxing 0.5 hour, solid does not dissolve entirely, adds the 1g gac, refluxes 30 minutes, filters, and filter cake is used hot water wash, drains, and the refrigerator cold-storage crystallization is put in the washing filtrate merging;
(2) suction filtration gained filtrating and crystalline mixture; Get crystallized product and at room temperature dissolved stir process 1 hour, add the dilution of 100ml water, with Hydrogen chloride system is transferred to neutrality then with 5% NaOH solution 100ml; After the stirred crystallization 2 hours; Suction filtration, get dry after the crystallized product washing ganciclovir 15.7g, impurity guanine content reduces to 0.46%.
Embodiment 2
A kind of guanine content is the process for purification of 1.19% 20g ganciclovir bullion, may further comprise the steps:
(1) drop into reaction flask with 15% formic acid solution 300ml, be warmed up to backflow, solid dissolves the back entirely and adds the 1g gac, refluxes 30 minutes, filters, and filter cake is used hot water wash, drains, and the refrigerator cold-storage crystallization is put in the washing filtrate merging;
(2) suction filtration gained filtrating and crystalline mixture; Get crystallized product and at room temperature dissolved stir process 1 hour, add the dilution of 100ml water, with Hydrogen chloride system is transferred to neutrality then with 5% NaOH solution 100ml; After the stirred crystallization 2 hours; Suction filtration, get dry after the crystallized product washing ganciclovir 16.1g, impurity guanine content reduces to 0.22%.
Embodiment 3
A kind of guanine content is the process for purification of 1.19% 20g ganciclovir bullion, may further comprise the steps:
(1) drop into reaction flask with 15% glacial acetic acid solution 300ml, be warmed up to backflow, solid dissolves the back entirely and adds the 1g gac, refluxes 30 minutes, filters, and filter cake is used hot water wash, drains, and the refrigerator cold-storage crystallization is put in the washing filtrate merging;
(2) suction filtration gained filtrating and crystalline mixture; Get crystallized product and at room temperature dissolved stir process 1 hour, add the dilution of 100ml water, with Hydrogen chloride system is transferred to neutrality then with 5% NaOH solution 100ml; After the stirred crystallization 2 hours; Suction filtration, get dry after the crystallized product washing ganciclovir 16.3g, impurity guanine content reduces to 0.42%.
Embodiment 4
A kind of guanine content is the process for purification of 1.19% 20g ganciclovir bullion, may further comprise the steps:
(1) drop into reaction flask with 10% formic acid solution 300ml, be warmed up to backflow, solid dissolves the back entirely and adds the 1g gac, refluxes 30 minutes, filters, and filter cake is used hot water wash, drains, and the refrigerator cold-storage crystallization is put in the washing filtrate merging;
(2) suction filtration gained filtrating and crystalline mixture; Get crystallized product and at room temperature dissolved stir process 1 hour, add the dilution of 100ml water, with Hydrogen chloride system is transferred to neutrality then with 5% NaOH solution 100ml; After the stirred crystallization 2 hours; Suction filtration, get dry after the crystallized product washing ganciclovir 16.2g, impurity guanine content reduces to 0.34%.
Embodiment 5
A kind of guanine content is the process for purification of 0.94% 20g ganciclovir bullion, may further comprise the steps:
(1) drop into reaction flask with 10% formic acid solution 300ml, be warmed up to backflow, solid dissolves the back entirely and adds the 1g gac, refluxes 30 minutes, filters, and filter cake is used hot water wash, drains, and the refrigerator cold-storage crystallization is put in the washing filtrate merging;
(2) suction filtration gained filtrating and crystalline mixture; Get crystallized product and at room temperature dissolved stir process 1 hour, add the dilution of 100ml water, with Hydrogen chloride system is transferred to neutrality then with 5% NaOH solution 100ml; After the stirred crystallization 2 hours; Suction filtration, get dry after the crystallized product washing ganciclovir 16.7g, impurity guanine content reduces to 0.24%.
Claims (3)
1. the process for purification of a ganciclovir is characterized in that: may further comprise the steps:
(1) in 1g: the ratio of 10~20ml adds the dissolving of lower fatty acid heated in water solution with the ganciclovir bullion, and the ratio that adds 0.05~0.10g in per 1 gram ganciclovir bullion adds gac, refluxes 30 minutes, filters insolubles, gets the filtrating crystallisation by cooling;
(2) suction filtration gained filtrating and crystalline mixture; Getting crystallized product, to use mass concentration be 2~10% inorganic alkali solution stir process 0.5~2.0 hour at room temperature; With hydrochloric acid system is transferred to neutrality then, stirred crystallization is after 2~6 hours, suction filtration; Get the crystallized product oven dry, get the qualified ganciclovir of guanine foreign matter content.
2. the process for purification of ganciclovir as claimed in claim 1, it is characterized in that: the lower fatty acid in the said step (1) is formic acid or acetate, mass concentration is 5~30%, ganciclovir bullion and the preferred 1g of lower aliphatic aqueous acid ratio: 15ml; Mineral alkali in the step (2) is sodium hydroxide or Pottasium Hydroxide, mass concentration preferred 5%.
3. the process for purification of ganciclovir as claimed in claim 2 is characterized in that: the lower fatty acid preferable formic acid in the said step (1); The preferred sodium hydroxide of mineral alkali in the step (2).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210104187.0A CN102627643B (en) | 2012-04-10 | 2012-04-10 | Refining method for ganciclovir |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210104187.0A CN102627643B (en) | 2012-04-10 | 2012-04-10 | Refining method for ganciclovir |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102627643A true CN102627643A (en) | 2012-08-08 |
CN102627643B CN102627643B (en) | 2014-01-08 |
Family
ID=46586061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210104187.0A Active CN102627643B (en) | 2012-04-10 | 2012-04-10 | Refining method for ganciclovir |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102627643B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059023A (en) * | 2012-12-31 | 2013-04-24 | 浙江车头制药股份有限公司 | Method for preparing ganciclovir crystal form II |
CN108358926A (en) * | 2018-04-28 | 2018-08-03 | 安徽海康药业有限责任公司 | A method of removal crystal's bulk pharmaceutical chemicals bacterial endotoxin |
CN113149987A (en) * | 2021-04-22 | 2021-07-23 | 南京杏药原医药科技开发有限公司 | Preparation method of injection-grade ganciclovir |
CN115504977A (en) * | 2022-09-23 | 2022-12-23 | 海南锦瑞制药有限公司 | Preparation method of ganciclovir and preparation method of ganciclovir for injection |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4355032A (en) * | 1981-05-21 | 1982-10-19 | Syntex (U.S.A.) Inc. | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent |
US4423050A (en) * | 1981-05-21 | 1983-12-27 | Syntex (U.S.A.) Inc. | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent |
CN101851239A (en) * | 2009-04-03 | 2010-10-06 | 上海益威实业有限公司 | Ganciclovir recovery method |
CN101851240A (en) * | 2009-04-03 | 2010-10-06 | 上海益威实业有限公司 | Ganciclovir purification process |
-
2012
- 2012-04-10 CN CN201210104187.0A patent/CN102627643B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4355032A (en) * | 1981-05-21 | 1982-10-19 | Syntex (U.S.A.) Inc. | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent |
US4355032B1 (en) * | 1981-05-21 | 1983-06-14 | ||
US4423050A (en) * | 1981-05-21 | 1983-12-27 | Syntex (U.S.A.) Inc. | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent |
US4355032B2 (en) * | 1981-05-21 | 1990-10-30 | 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent | |
CN101851239A (en) * | 2009-04-03 | 2010-10-06 | 上海益威实业有限公司 | Ganciclovir recovery method |
CN101851240A (en) * | 2009-04-03 | 2010-10-06 | 上海益威实业有限公司 | Ganciclovir purification process |
Non-Patent Citations (1)
Title |
---|
文宁锋: "更昔洛韦的合成", 《中国优秀博硕士学位论文全文数据库(硕士)工程科技I辑 B016-459》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059023A (en) * | 2012-12-31 | 2013-04-24 | 浙江车头制药股份有限公司 | Method for preparing ganciclovir crystal form II |
CN103059023B (en) * | 2012-12-31 | 2015-09-30 | 浙江车头制药股份有限公司 | A kind of method preparing ganciclovir crystal form II |
CN108358926A (en) * | 2018-04-28 | 2018-08-03 | 安徽海康药业有限责任公司 | A method of removal crystal's bulk pharmaceutical chemicals bacterial endotoxin |
CN113149987A (en) * | 2021-04-22 | 2021-07-23 | 南京杏药原医药科技开发有限公司 | Preparation method of injection-grade ganciclovir |
CN113149987B (en) * | 2021-04-22 | 2023-09-15 | 南京杏药原医药科技开发有限公司 | Preparation method of injection-grade ganciclovir |
CN115504977A (en) * | 2022-09-23 | 2022-12-23 | 海南锦瑞制药有限公司 | Preparation method of ganciclovir and preparation method of ganciclovir for injection |
CN115504977B (en) * | 2022-09-23 | 2024-02-09 | 海南锦瑞制药有限公司 | Preparation method of ganciclovir and preparation method of ganciclovir for injection |
Also Published As
Publication number | Publication date |
---|---|
CN102627643B (en) | 2014-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102321122B (en) | Method for preparing sucralose from sucralose-6-acetate | |
CN102627643B (en) | Refining method for ganciclovir | |
CN106256824B (en) | Preparation method of high-purity delafloxacin meglumine salt | |
CN102276663A (en) | Preparation method of glucosamine sulfate | |
CN105085522A (en) | Method for preparing high-purity moxifloxacin hydrochloride | |
CN111440170B (en) | Method for synthesizing guanine by using guanosine | |
CN102060860B (en) | Preparation method of Marbofloxacin | |
CN101851240B (en) | Ganciclovir purification process | |
CN104356146A (en) | Method for preparing cefotiam hydrochloride | |
CN109503585A (en) | A kind of refining methd of pentoxifylline recovery article | |
CN105330581A (en) | Preparation method for (S)-oxiracetam | |
CN103923083A (en) | Adenine synthesis technology | |
CN109867673B (en) | Method for synthesizing palbociclib | |
CN103122017A (en) | Refining method of vidarabine monophosphate | |
CN102146052B (en) | Method for preparing tryptophan | |
CN104327129A (en) | Method for preparing glucosamine hydrochloride by taking crab shells as raw materials | |
CN103709164B (en) | A kind of synthetic method of adenine | |
CN104557969A (en) | Production technique of clopidogrel hydrogen sulfate | |
CN104119243A (en) | Iminodiacetic acid energy saving cleaning production method | |
CN105440035A (en) | Low-energy-consumption preparation method for synthesizing high-purity folic acid | |
CN102643277B (en) | Refining method of ganciclovir | |
CN103664952B (en) | A kind of preparation method of Zopiclone | |
CN102127081A (en) | Preparation method of adenine | |
CN104610385B (en) | A kind of process for purification of aminoglucose hydrochloride | |
CN106748721A (en) | A kind of preparation method of the iodo-benzoic acid of 2 chlorine 5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 213105 Changzhou, Wujin District, Luoyang City, Dai Dai Street Patentee after: Kang Li (Changzhou) Medicine Pharmaceutical Co. Ltd. Address before: 213105 Changzhou, Wujin District, Luoyang City, Dai Dai Street Patentee before: Changzhou Kangli Pharmaceutical Co., Ltd. |